Aileron Therapeutics, Inc. (NASDAQ:ALRN) – Equities researchers at William Blair issued their Q1 2018 earnings per share (EPS) estimates for Aileron Therapeutics in a note issued to investors on Friday. William Blair analyst Y. Xu forecasts that the company will earn ($0.49) per share for the quarter. William Blair has a “Outperform” rating on the stock.

WARNING: This news story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/11/13/william-blair-comments-on-aileron-therapeutics-inc-s-q1-2018-earnings-alrn.html.

ALRN has been the subject of several other research reports. Canaccord Genuity started coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They set a “buy” rating and a $19.00 target price for the company. Jefferies Group LLC started coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They set a “buy” rating and a $20.00 target price for the company. Finally, Bank of America Corporation started coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They set a “buy” rating and a $19.00 target price for the company.

Shares of Aileron Therapeutics (NASDAQ:ALRN) opened at $11.58 on Monday. Aileron Therapeutics has a 12 month low of $9.58 and a 12 month high of $15.48.

A number of large investors have recently made changes to their positions in ALRN. Jennison Associates LLC acquired a new stake in Aileron Therapeutics in the second quarter valued at about $2,788,000. Candriam Luxembourg S.C.A. acquired a new stake in Aileron Therapeutics in the second quarter valued at about $1,673,000. Sphera Funds Management LTD. acquired a new stake in Aileron Therapeutics in the second quarter valued at about $1,394,000. Nexthera Capital LP acquired a new stake in Aileron Therapeutics in the second quarter valued at about $1,272,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Aileron Therapeutics in the second quarter valued at about $418,000. Hedge funds and other institutional investors own 12.39% of the company’s stock.

About Aileron Therapeutics

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.